Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADMA 
ADMA Biologics Inc (ADMA)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: ADMA (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $29.06
1 Year Target Price $29.06
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 144.75% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.12B USD | Price to earnings Ratio 20.31 | 1Y Target Price 29.06 |
Price to earnings Ratio 20.31 | 1Y Target Price 29.06 | ||
Volume (30-day avg) 3 | Beta 0.38 | 52 Weeks Range 13.50 - 25.67 | Updated Date 08/29/2025 |
52 Weeks Range 13.50 - 25.67 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.15 | Actual 0.14 |
Profitability
Profit Margin 44.06% | Operating Margin (TTM) 35.09% |
Management Effectiveness
Return on Assets (TTM) 20.81% | Return on Equity (TTM) 71.23% |
Valuation
Trailing PE 20.31 | Forward PE 28.99 | Enterprise Value 4140941896 | Price to Sales(TTM) 8.69 |
Enterprise Value 4140941896 | Price to Sales(TTM) 8.69 | ||
Enterprise Value to Revenue 8.73 | Enterprise Value to EBITDA 25.39 | Shares Outstanding 238631008 | Shares Floating 233862877 |
Shares Outstanding 238631008 | Shares Floating 233862877 | ||
Percent Insiders 2.57 | Percent Institutions 90.71 |
Upturn AI SWOT
ADMA Biologics Inc
Company Overview
History and Background
ADMA Biologics, Inc. was founded in 2004. It's a biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived products for the treatment of immune deficiencies and infectious diseases.
Core Business Areas
- Plasma Collection: ADMA operates its own FDA-approved plasma collection centers to source raw material for its products.
- Manufacturing: ADMA manufactures plasma-derived therapies, including intravenous immune globulin (IVIG) products.
- Commercialization: ADMA commercializes and distributes its products to hospitals, pharmacies, and other healthcare providers.
Leadership and Structure
ADMA is led by a management team with experience in the biopharmaceutical industry. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- BIVIGAMu00ae: Intravenous Immune Globulin (IVIG) indicated for the treatment of primary humoral immunodeficiency (PI). Competitors include Grifols (GRFS), CSL Behring, Takeda (TAK), and Kedrion Biopharma. BIVIGAM revenue for 2023 was $135.1 million. Market share data specifically for BIVIGAM is difficult to ascertain precisely due to the broader IVIG market.
- ASCENIVu2122: Intravenous Immune Globulin (IVIG) indicated for the treatment of primary humoral immunodeficiency (PI). Competitors include Grifols (GRFS), CSL Behring, Takeda (TAK), and Kedrion Biopharma. ASCENIV revenue for 2023 was $45.8 million. Market share data specifically for ASCENIV is difficult to ascertain precisely due to the broader IVIG market.
- NABI-HBu00ae: Hepatitis B Immune Globulin (Human) for post-exposure prophylaxis. Competitors include Grifols (GRFS). Market share data specifically for NABI-HB is not readily available.
Market Dynamics
Industry Overview
The plasma-derived therapies market is growing due to increasing prevalence of immune deficiencies and infectious diseases. High demand and limited supply characterize the market.
Positioning
ADMA is a smaller player compared to industry giants but focuses on niche markets and vertically integrated operations (plasma collection).
Total Addressable Market (TAM)
The global immunoglobulin market is projected to reach USD 16.6 billion by 2029. ADMA is well-positioned to capture a portion of this TAM with its specialized IVIG products and control over plasma supply.
Upturn SWOT Analysis
Strengths
- Vertically integrated operations (plasma collection)
- Specialized IVIG products
- FDA-approved manufacturing facilities
- Focus on niche markets
Weaknesses
- Smaller scale compared to larger competitors
- Reliance on plasma supply
- Limited product portfolio
- High debt levels
Opportunities
- Expanding plasma collection network
- Developing new plasma-derived therapies
- Acquiring complementary businesses
- Increasing market share in niche areas
Threats
- Competition from larger players
- Fluctuations in plasma supply
- Regulatory changes
- Pricing pressures
Competitors and Market Share
Key Competitors
- GRFS
- CSL
- TAK
Competitive Landscape
ADMA is a smaller player competing with established giants. Its vertical integration and specialized products provide a competitive edge in niche markets.
Major Acquisitions
Plasma Centers
- Year: 2022
- Acquisition Price (USD millions): 32.5
- Strategic Rationale: To increase plasma supply and reduce reliance on third-party suppliers.
Growth Trajectory and Initiatives
Historical Growth: ADMA has experienced significant revenue growth in recent years, driven by increased sales of its IVIG products.
Future Projections: Analysts expect continued revenue growth as ADMA expands its plasma collection network and introduces new products. Profitability is expected in the near future.
Recent Initiatives: Expansion of plasma collection centers, strategic acquisitions, and investment in R&D are recent initiatives.
Summary
ADMA Biologics shows potential with its growing revenue and strategic focus on plasma-derived therapies, particularly IVIG. While losses persist, improving gross margins and plasma collection expansion are positives. However, ADMA needs to address its debt and navigate competition to achieve sustainable profitability. Long term strategic goals need to be put in place.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Presentations
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary based on source. Financial data is based on publicly available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ADMA Biologics Inc
Exchange NASDAQ | Headquaters Ramsey, NJ, United States | ||
IPO Launch date 2013-10-17 | Co-Founder, President, CEO & Director Mr. Adam S. Grossman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 685 | Website https://www.admabiologics.com |
Full time employees 685 | Website https://www.admabiologics.com | ||
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.